Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Patritumab |
| Synonyms | |
| Therapy Description |
Patritumab (U3-1287) is a monoclonal antibody that targets HER3 and inhibits ligand binding, potentially resulting in decreased activation of downstream signaling and reduced tumor growth (PMID: 24442032, PMID: 31648099). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Patritumab | U3-1287|AMG-888 | HER3 (ERBB3) Antibody 30 | Patritumab (U3-1287) is a monoclonal antibody that targets HER3 and inhibits ligand binding, potentially resulting in decreased activation of downstream signaling and reduced tumor growth (PMID: 24442032, PMID: 31648099). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 over exp | prostate cancer | predicted - sensitive | Patritumab | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Patritumab (U3-1287) treatment decreased viability of patient-derived prostate cancer cells with high ERBB3 (HER3) expression in culture but did not inhibit tumor growth in a patient-derived xenograft (PDX) model, and did not demonstrate anti-tumor activity in cell lines with low ERBB3 (HER3) expression (PMID: 34753775). | 34753775 |
| ERBB3 positive | colorectal cancer | predicted - sensitive | Patritumab | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Patritumab treatment resulted in reduced Erbb3 (Her3) phosphorylation in Erbb3 (Her3)-positive colorectal cancer cell lines in culture and modest antitumor activity in cell line xenograft models (PMID: 31395690). | 31395690 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|